Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC16 smallpox vaccine post-exposure prophylaxis study for mpox
jRCTs031220137Completed
- Sponsor
- Health and Labour Sciences Research Grants
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of LC16m8 smallpox vaccine in mpox, sponsored by Health and Labour Sciences Research Grants. Primary endpoint: Onset of disease 21 days after intense contact. Started Jul 2022; status: completed.
02
Drugs
LC16m8 smallpox vaccine
03
Conditions
mpox
Beyond the preview
Go deeper on jRCTs031220137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220137.